• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

SubjectWell Raises $10M to Expand Its Risk-Free Patient Recruitment Marketplace

Share:

June 25, 2019

SubjectWell, the risk-free clinical trials marketplace for patient recruitment, announced today its $10 million in Series A funding led by Windham Venture Partners, with participation from previous investors Healthy Ventures and Geekdom Fund. This funding bolsters SubjectWell’s mission of building awareness of and increasing participation in clinical research by providing a single marketplace that allows prospective patients to match to any available clinical trials.

“The largest barrier to participation in clinical trials is awareness — patients aren’t aware clinical trials exist and don’t know how to get started,” said Ivor Clarke, CEO at SubjectWell. “By building awareness and creating the first true trial marketplace, we provide patients with greater choice and access to innovative treatments. Our investors’ support allows us to reach more interested patients and fill our clients’ studies faster.”

This round of funding will support SubjectWell’s international expansion by helping the company extend its services beyond North America and into Europe, South America, and the United Kingdom.

“Our growth is not just deepening the patient pool,” said Tony Averbeck, vice president of business development at SubjectWell. “Our performance-based pricing model, where we’re only compensated for patients who randomize, is specifically designed to allow every sponsor to bring all of their trials into SubjectWell’s marketplace.”

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Despite all the recent advances in medicine, clinical trials continue to be a major pain point for stakeholders. The vast majority of trials are delayed and many ultimately fail due to poor patient selection,” said Adam Fine, general partner and CEO at Windham. “We have looked deeply at the clinical trial space and concluded that SubjectWell, with hundreds of studies already recruiting through its marketplace, has demonstrated the most effective model for enrolling clinical trials. We are excited to partner with this terrific team.”

Date: June 25, 2019

Source: Digital Journal

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • XORTX Announces Closing of US$5 Million Public OfferingXORTX Announces Closing of US$5 Million Public Offering
  • Charlotte-Based Public-Private Partnership Provides How-To Guide For Mass Vaccination EventsCharlotte-Based Public-Private Partnership Provides How-To Guide For Mass Vaccination Events
  • Healthcare Needs AI, AI Needs CausalityHealthcare Needs AI, AI Needs Causality
  • Efforts to Make Contact Tracing Technology Available on WearablesEfforts to Make Contact Tracing Technology Available on Wearables
  • Centene and CVS Health Announce Agreement for CVS Health to Acquire IlliniCare HealthCentene and CVS Health Announce Agreement for CVS Health to Acquire IlliniCare Health
  • Zydus Lifesciences FDA Compliance Q1 ResultsZydus Lifesciences FDA Compliance Q1 Results
  • Welltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health DealsWelltok Adds Four New Digital Programs, Atrium Health Adopts Butterfly’s Handheld Ultrasound and More Digital Health Deals
  • Amazon Alexa Devices Can Now Answer Medication-Related QuestionsAmazon Alexa Devices Can Now Answer Medication-Related Questions

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications